LiG‐AuNPs show potential for treating GSK‐3β‐related conditions like mood disorders, Alzheimer's disease, and viral infections through prolonged, targeted administration. The gene discussed is GSK3B; the disease is early-onset autosomal dominant Alzheimer disease.